- $78.55m
- $120.10m
- $54.22m
- 59
- 26
- 77
- 54
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 8.89 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.45 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -53.5% | ||
| Return on Equity | -232.51% | ||
| Operating Margin | -77.95% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | 21.34 | 17.98 | 22.77 | 54.22 | 65.54 | 70.47 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Celularity Inc. is a regenerative and cellular medicine company. The Company is developing and commercializing advanced biomaterial products and allogeneic, cryopreserved, placental-derived cell therapies, all derived from the postpartum placenta. Its therapeutic programs target aging-related diseases, including degenerative diseases, cancer, and immune disorders, using mesenchymal-like adherent stromal cells, T-cells engineered with CAR (CAR T-cells), and genetically modified and unmodified natural killer (NK) cells. It develops, manufactures and commercializes advanced biomaterial products derived from structural tissue components of the postpartum placental tissues, including the umbilical cord. Its advanced biomaterials include Celularity Tendon Wrap, FUSE Bone Void Filler and Celularity Placental Matrix. Its advanced biomaterial products include Biovance, Biovance 3L, CentaFlex, Interfyl and Rebound products.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- August 24th, 2018
- Public Since
- May 23rd, 2019
- No. of Shareholders
- 96
- No. of Employees
- 123
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 23,949,229
- Address
- 170 Park Ave, FLORHAM PARK, 07932
- Web
- https://celularity.com/
- Phone
- +1 9087682170
- Contact
- Carlos Ramirez
- Auditors
- Deloitte & Touche LLP
Upcoming Events for CELU
Q2 2025 Celularity Inc Earnings Release
Q3 2025 Celularity Inc Earnings Release
Celularity Inc Annual Shareholders Meeting
Similar to CELU
60 Degrees Pharmaceuticals
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
Adaptimmune Therapeutics
NASDAQ Capital Market
Akari Therapeutics
NASDAQ Capital Market
Akebia Therapeutics
NASDAQ Capital Market
FAQ
What is the Celularity share price?
As of Today at 01:50 UTC, shares in Celularity are trading at $3.28. This share price information is delayed by 15 minutes.
How has the Celularity share price performed this year?
Shares in Celularity last closed at $3.28 and the price had moved by +4.13% over the past 365 days. In terms of relative price strength the Celularity share price has underperformed the S&P500 Index by -10.54% over the past year.
What are the analyst and broker recommendations for Celularity?
The overall consensus recommendation for Celularity is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Celularity dividend yield?
Celularity does not currently pay a dividend.
Does Celularity pay a dividend?
Celularity does not currently pay a dividend.
When does Celularity next pay dividends?
Celularity does not currently pay a dividend.
How do I buy Celularity shares?
To buy shares in Celularity you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Celularity?
As of the previous close price of $3.28, shares in Celularity had a market capitalisation of $78.55m.
Where are Celularity shares listed?
Here are the trading details for Celularity:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: CELU
What kind of share is Celularity?
Based on an overall assessment of its quality, value and momentum Celularity is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Celularity share price forecast for 2025?
The analyst consensus target price for shares in Celularity is $2.50. That is 23.78% below the last closing price of $3.28.
Analysts covering Celularity currently have a consensus Earnings Per Share (EPS) forecast of -$0.42 for the next financial year.
Find out moreWhat is the trend in the Celularity share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Celularity. Over the past six months, its share price has outperformed the S&P500 Index by +51.3%.
As of the last closing price of $3.28, shares in Celularity were trading +57.61% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Celularity PE Ratio?
The Celularity PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $3.28.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Celularity?
We do not have data on Celularity's directors